Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - capecitabine, quantity: 150 mg - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; hypromellose; croscarmellose sodium; titanium dioxide; purified talc; magnesium stearate; iron oxide red - colon cancer,capecitabine sandoz is indicated for the adjuvant treatment of patients with dukes' stage c and high-risk stage b, colon cancer, either as monotherapy or in combination with oxaliplatin.,colorectal cancer,capecitabine sandoz is indicated for the treatment of patients with advanced or metastatic colorectal cancer.,oesophagogastric cancer,capecitabine sandoz is indicated for the first-line treatment of patients with advanced oesophagogastric cancer in combination with a platinum-based regimen.,breast cancer,capecitabine sandoz is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen unless therapy with these and other standard agents are clinically contraindicated.,capecitabine sandoz in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - alogliptin benzoate, quantity: 17 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; macrogol 8000; hypromellose; hyprolose; mannitol; titanium dioxide; iron oxide yellow; microcrystalline cellulose; magnesium stearate; shellac; ethanol absolute; iron oxide black; 1-butanol - nesina is indicated to improve glycaemic control in adult patients (>= 18 years old) with type 2 diabetes mellitus when diet and exercise do not provide adequate glycaemic control, as add on to metformin, a sulphonylurea, a thiazolidinedione, insulin (with or without metformin), or in combination with metformin and a thiazolidinedione when dual therapy does not provide adequate glycaemic control.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - alogliptin benzoate, quantity: 8.5 mg - tablet, film coated - excipient ingredients: titanium dioxide; croscarmellose sodium; magnesium stearate; mannitol; macrogol 8000; hyprolose; hypromellose; iron oxide red; microcrystalline cellulose; shellac; ethanol absolute; iron oxide black; 1-butanol - nesina is indicated to improve glycaemic control in adult patients (>= 18 years old) with type 2 diabetes mellitus when diet and exercise do not provide adequate glycaemic control, as add on to metformin, a sulphonylurea, a thiazolidinedione, insulin (with or without metformin), or in combination with metformin and a thiazolidinedione when dual therapy does not provide adequate glycaemic control.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - alogliptin benzoate, quantity: 34 mg - tablet, film coated - excipient ingredients: iron oxide red; titanium dioxide; mannitol; magnesium stearate; croscarmellose sodium; hypromellose; microcrystalline cellulose; macrogol 8000; hyprolose; shellac; ethanol absolute; iron oxide black; 1-butanol - nesina is indicated to improve glycaemic control in adult patients (>= 18 years old) with type 2 diabetes mellitus when diet and exercise do not provide adequate glycaemic control, as add on to metformin, a sulphonylurea, a thiazolidinedione, insulin (with or without metformin), or in combination with metformin and a thiazolidinedione when dual therapy does not provide adequate glycaemic control.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - irbesartan, quantity: 150 mg - tablet, film coated - excipient ingredients: hypromellose; lactose monohydrate; purified talc; microcrystalline cellulose; titanium dioxide; hyprolose; croscarmellose sodium; magnesium stearate; colloidal anhydrous silica; macrogol 6000 - indicated for the treatment of hypertension. indicated for delaying the progression of renal disease in hypertensive type ii diabetics with persistent micro-albuminuria (greater than or equal to 30mg per 24 hours) or urinary protein in excess of 900mg per 24 hours.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - irbesartan, quantity: 300 mg - tablet, film coated - excipient ingredients: magnesium stearate; hyprolose; croscarmellose sodium; lactose monohydrate; hypromellose; microcrystalline cellulose; titanium dioxide; purified talc; macrogol 6000; colloidal anhydrous silica - indicated for the treatment of hypertension. indicated for delaying the progression of renal disease in hypertensive type ii diabetics with persistent micro-albuminuria (greater than or equal to 30mg per 24 hours) or urinary protein in excess of 900mg per 24 hours.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - irbesartan, quantity: 75 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; lactose monohydrate; purified talc; hyprolose; hypromellose; magnesium stearate; macrogol 6000; croscarmellose sodium; titanium dioxide - indicated for the treatment of hypertension. indicated for delaying the progression of renal disease in hypertensive type ii diabetics with persistent micro-albuminuria (greater than or equal to 30mg per 24 hours) or urinary protein in excess of 900mg per 24 hours.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - quetiapine fumarate, quantity: 115.13 mg (equivalent: quetiapine, qty 100 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; calcium hydrogen phosphate dihydrate; iron oxide yellow; sodium starch glycollate type a; silicon dioxide; povidone; magnesium stearate; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 4000 - quetiapine sandoz is indicated for:,bipolar disorder adults ? maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes ? treatment of depressive episodes associated with bipolar disorder (see dose and method of administration) ? treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate,children/adolescents aged 10 to 17 years ? monotherapy treatment of acute mania associated with bipolar i disorder,schizophrenia (adults and adolescents aged 13 to 17 years) ? treatment of schizophrenia

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - quetiapine fumarate, quantity: 345.39 mg (equivalent: quetiapine, qty 300 mg) - tablet, film coated - excipient ingredients: povidone; calcium hydrogen phosphate dihydrate; silicon dioxide; lactose monohydrate; microcrystalline cellulose; magnesium stearate; sodium starch glycollate type a; titanium dioxide; hypromellose; macrogol 4000 - quetiapine sandoz is indicated for:,bipolar disorder adults ? maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes ? treatment of depressive episodes associated with bipolar disorder (see dose and method of administration) ? treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate,children/adolescents aged 10 to 17 years ? monotherapy treatment of acute mania associated with bipolar i disorder,schizophrenia (adults and adolescents aged 13 to 17 years) ? treatment of schizophrenia

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - quetiapine fumarate, quantity: 28.78 mg (equivalent: quetiapine, qty 25 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; silicon dioxide; iron oxide yellow; sodium starch glycollate type a; povidone; magnesium stearate; iron oxide red; calcium hydrogen phosphate dihydrate; titanium dioxide; hypromellose; macrogol 4000 - quetiapine sandoz is indicated for:,bipolar disorder adults ? maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes ? treatment of depressive episodes associated with bipolar disorder (see dose and method of administration) ? treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate,children/adolescents aged 10 to 17 years ? monotherapy treatment of acute mania associated with bipolar i disorder,schizophrenia (adults and adolescents aged 13 to 17 years) ? treatment of schizophrenia